If you a patient with ATTRv with polyneuropathy, or a carer, friend, family member or health professional treating a patient with these problems the PBAC invites you to make a submission on their consumer portal
AMVUTTRA®(vutrisiran) to treat hATTR also referred to as ATTRv in patients with stage 1 and 2 polyneuropathy, is scheduled on the November 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda to request a General Schedule Authority Required (Written) PBS listing for the treatment of hATTR/HTTRv amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
The PBAC has opened the consumer portal for comments for submission by September 25, 2024 (now expired)
